Clinical trials
Terminated Phase 1 trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
4,405 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 17 |
| 2001 | 19 |
| 2002 | 25 |
| 2003 | 46 |
| 2004 | 59 |
| 2005 | 89 |
| 2006 | 117 |
| 2007 | 167 |
| 2008 | 168 |
| 2009 | 192 |
| 2010 | 198 |
| 2011 | 196 |
| 2012 | 189 |
| 2013 | 161 |
| 2014 | 218 |
| 2015 | 223 |
| 2016 | 240 |
| 2017 | 250 |
| 2018 | 248 |
| 2019 | 291 |
| 2020 | 276 |
| 2021 | 304 |
| 2022 | 255 |
| 2023 | 185 |
| 2024 | 148 |
| 2025 | 59 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 4,405 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 144 |
| Pfizer | 117 |
| M.D. Anderson Cancer Center | 82 |
| GlaxoSmithKline | 81 |
| AstraZeneca | 80 |
| Novartis Pharmaceuticals | 78 |
| Merck Sharp & Dohme LLC | 70 |
| Boehringer Ingelheim | 67 |
| Washington University School of Medicine | 57 |
| Eli Lilly and Company | 45 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 305 |
| Carcinoma, Non-Small-Cell Lung | 268 |
| Leukemia, Myeloid, Acute | 202 |
| Breast Neoplasms | 175 |
| Melanoma | 167 |
| Neoplasm Metastasis | 159 |
| Recurrence | 136 |
| Multiple Myeloma | 134 |
| Colorectal Neoplasms | 127 |
| Lymphoma, Non-Hodgkin | 121 |
Trials
Showing 1 to 25 of 4,405. Each trial links to its page on Pharma Observatory.
4,305 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.